Teva says first-quarter sales of Copaxone for multiple sclerosis up 29% to $329 million

By E. Janene Geiss

Philadelphia, May 5 - Teva Pharmaceutical Industries Ltd. said Friday that global in-market sales of Copaxone reached a record $329 million in the first quarter ended March 31.

Once again, Copaxone was the fastest growing multiple sclerosis therapy worldwide with a growth of 29% in sales over the comparable quarter of 2005, according to a company news release.

U.S. sales in the first quarter of 2006 increased 36% over the first quarter of 2005 to $221 million.

According to IMS data in the United States, Copaxone continued to strengthen its position as the market leader, reaching a market share of 34.9% in new prescriptions in March.

For the first quarter, sales outside the United States, mainly in Europe, increased by 17% over the comparable quarter of 2005 to $108 million, officials said.

Teva, based in Jerusalem, Israel, develops, manufactures and markets generic pharmaceuticals and active pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.